InspireMD, Inc. Form 10-Q August 06, 2018
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended: June 30, 2018
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE [] ACT OF 1934
For the transition period from to
Commission file number: 001-35731
InspireMD, Inc.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation or organization)	
4 Menorat Hamaor St.	
Tel Aviv, Israel 6744832	
(Address of principal executive	e offices)
(Zip Code)	
(888) 776-6204	
(Registrant's telephone number	r, including area code)
Securities Exchange Act of 193	er registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the 34 during the preceding 12 months (or for such shorter period that the registrant was nd (2) has been subject to such filing requirements for the past 90 days. Yes [X] No []
any, every Interactive Data File	er the registrant has submitted electronically and posted on its corporate Web site, if e required to be submitted and posted pursuant to Rule 405 of Regulation S-T during or such shorter period that the registrant was required to submit and post such files).
Yes [X] No []	
smaller reporting company, or	er the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a an emerging growth company. See definitions of "large accelerated filer," "accelerated any" and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer [] Non-accelerated filer [] Smaller reporting company [X	Accelerated filer [] (Do not check if a smaller reporting company) Emerging growth company []
	ry, indicate by check mark if the registrant has elected not to use the extended transition new or revised financial accounting standards provided pursuant to Section 13(a) of the

Edgar Filing: InspireMD, Inc. - Form 10-Q

Indicate by	check mark	whether t	he registran	t is a shell	company	(as	defined in	n Rule	12b-2 d	of the	Exchange	e Act)	١.

Yes [] No [X]

The number of shares of the registrant's common stock, \$0.0001 par value, outstanding as of August 6, 2018: 23,784,846

Edgar Filing: InspireMD, Inc. - Form 10-Q

TABLE OF CONTENTS

		Page
	PART I	
Item 1.	Financial Statements	F-1
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	3
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	12
Item 4.	Controls and Procedures	12
	<u>PART II</u>	
Item 1.	<u>Legal Proceedings</u>	13
Item 1A.	Risk Factors	13
Item 5.	Other Information	34
Item 6.	<u>Exhibits</u>	34

2

INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

June 30, 2018

F-1

INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

June 30, 2018

TABLE OF CONTENTS

	Page
Consolidated Balance Sheets	F-3 - F-4
Consolidated Statements of Operations	F-5
Consolidated Statements of Changes in Equity	F-6
Consolidated Statements of Cash Flows	F-7
Notes to the Consolidated Financial Statements	F-8 - F-20

The amounts are stated in U.S. dollars in thousands

F-2

CONSOLIDATED BALANCE SHEETS

(Unaudited)

(U.S. dollars in thousands)

	June 30, 2018	December 31, 2017
ASSETS		
CURRENT ASSETS:		
Cash and cash equivalents	6,442	3,710
Accounts receivable:		
Trade, net	916	643
Other	175	207
Prepaid expenses	71	62
Inventory	637	533
TOTAL CURRENT ASSETS	8,241	5,155
NON-CURRENT ASSETS:		
Property, plant and equipment, net	431	476
Deferred Issuance Costs	310	-
Funds in respect of employee rights upon retirement	489	476
TOTAL NON-CURRENT ASSETS	1,230	952
TOTAL ASSETS	9,471	6,107

CONSOLIDATED BALANCE SHEETS

(Unaudited)

(U.S. dollars in thousands other than share and per share data)

LIABILITIES AND EQUITY	June 30, 2018	December 31, 2017
CURRENT LIABILITIES: Accounts payable and accruals: Trade Other Contract liability TOTAL CURRENT LIABILITIES	476 1,978 26 2,480	328 2,134 20 2,482
LONG-TERM LIABILITIES- Liability for employees rights upon retirement TOTAL LONG-TERM LIABILITIES	629 629	624 624
COMMITMENTS AND CONTINGENT LIABILITIES (Note 8) TOTAL LIABILITIES REDEEMABLE PREFFERED SHARES	3,109 2,264	3,106 274
EQUITY: Common stock, par value \$0.0001 per share; 150,000,000 shares authorized at June 30, 2018 and December 31, 2017; 6,453,428 and 1,483,556 shares issued and outstanding at June 30, 2018 and December 31, 2017, respectively Preferred B shares, par value \$0.0001 per share; 500,000 shares authorized at June 30, 2018	-	-
and December 31, 2017; 17,303 and 27,075 shares issued and outstanding at June 30, 2018 and December 31, 2017, respectively Preferred C shares, par value \$0.0001 per share; 1,172,000 shares authorized at June 30, 2018 and December 31, 2017; 378,840* and 741,651 shares issued and outstanding at June 30,	-	-
2018 and December 31, 2017, respectively Preferred D shares, par value \$0.0001 per share; 750 shares authorized at June 30, 2018 and December 31, 2017; 300** and 750 shares issued and outstanding at June 30, 2018 and December 31, 2017, respectively	-	-
Additional paid-in capital Accumulated deficit Total equity Total liabilities, redeemable preferred shares and equity	147,466 (143,368) 4,098 9,471	143,079 (140,352) 2,727 6,107

Edgar Filing: InspireMD, Inc. - Form 10-Q

* Including 306,917 shares that are classified in Redeemable Preferred Shares and were redeemed in full on July 3, 2018.

** The 300 shares are classified in Redeemable Preferred Shares and were redeemed in full on July 3, 2018.

The accompanying notes are an integral part of the interim consolidated financial statements.

F-4

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

(U.S. dollars in thousands, except per share data)

	Three months ended		Six months ended			
	June 30),	June 30,			
	2018	2017	2018	2017		
REVENUES	\$1,003	\$640	\$2,010	\$1,209		
COST OF REVENUES	726	493	1,440	988		
GROSS PROFIT	277	147	570	221		
OPERATING EXPENSES:						
Research and development	230	403	482			